M.D. Anderson Cancer Center
To learn if MGD019 can help to control cervical cancer in patients who have yet to receive treatment.
Primary Objectives: To estimate disease control rate (DCR) in patients with metastatic, recurrent, or persistent cervical cancer who have not received prior systemic chemotherapy and are undergoing induction immunotherapy with MGD019. Secondary Objectives: 1. To determine overall survival (OS) 2. To determine progression-free survival (PFS) 3. To determine objective response rate (ORR) 4. To determine duration of response (DOR) 5. To evaluate safety of administering MGD019 in cervical cancer patients using the National Institute of Health Common Terminology Criteria for Adverse Events (CTCA…
Inclusion Criteria: Inclusion criteria will be assessed within 28 days of starting study treatment: 1. Ability to provide signed informed consent 2. Age ≥ 18 years at time of study entry 3. Willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up 4. Biopsy or CT scan confirmed recurrent, metastatic, or persistent cervical cancer 5. One of the following histologic subtypes: squamous cell carcinoma, adenosquamous, or adenocarcinoma 6. Not amenable to curative treatment (e.g. surgery and/o…
Given by vein (IV)
Arctuva estimate
Verify or correct the compensation shown for this listing.